Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.

22 Feb 2011

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint.

19 Feb 2011

2 bills to expand mental health coverage introduced

Two bills to expand mental health coverage were introduced Thursday.

19 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

Metallic copper surfaces kill bacteria on contact

Metallic copper surfaces kill microbes on contact, decimating their populations, according to a paper in the February 2011 issue of the journal Applied and Environmental Microbiology. They do so literally in minutes, by causing massive membrane damage after about a minute's exposure, says the study's corresponding author, Gregor Grass of the University of Nebraska, Lincoln. This is the first study to demonstrate this mechanism of bacteriocide.

17 Feb 2011

Spirulina Pacifica supplement may improve immune function, anemia in senior citizens

Cyanotech Corporation, world leader in microalgae-based health and nutrition supplements, announced today that researchers at the University of California at Davis have determined that microalgae-based Hawaiian Spirulina Pacifica may improve immune function and ameliorate anemia in persons over 50.

17 Feb 2011

Viewpoints: Expediting SCOTUS health law review; birth control funding; budget cutting and the stock market

Virginia Attorney General Ken Cuccinelli II has asked the U.S. Supreme Court to take the extraordinary step of leapfrogging past federal appeals courts to decide the constitutionality of the new health-care law.

15 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

SynthRx to become wholly-owned subsidiary of ADVENTRX

ADVENTRX Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement to acquire SynthRx, Inc., a private biotechnology company developing a purified form of a rheologic and antithrombotic agent, poloxamer 188.

14 Feb 2011

Silent strokes can cause long-term cognitive, learning deficits in children with sickle cell disease

Silent strokes, which have no immediate symptoms but could cause long-term cognitive and learning deficits, occur in a significant number of severely anemic children, especially those with sickle cell disease, according to research presented at the American Stroke Association's International Stroke Conference 2011.

13 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Mobily introduces first mobile medical imaging service

Saudi Arabian telecommunications company Mobily and Great Connection Inc., creator of the innovative Mobile Baby service, announced the launch of the first mobile medical imaging service that enables ultrasound stills, 3D images and video clips to be sent directly from an ultrasound machine to a mobile device.

9 Feb 2011

Gates Foundation awards USF $5.45M for malaria research

The University of South Florida received $5.45 million in grants from the Bill & Melinda Gates Foundation. The first grant is to create advanced devices that mimic the human liver to better study the life cycle of the malaria parasite - particularly the elusive liver stage where the disease may be most vulnerable to attack.

9 Feb 2011

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has received a Notice of Non-Compliance (NON) from Health Canada regarding its New Drug Submission (NDS) for Feraheme® (ferumoxytol) injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.

9 Feb 2011

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

9 Feb 2011

Executive wellness a legit corporate expense

At least once a year, executives from Ciena Corp. spend a day at Johns Hopkins University getting poked and prodded as they undergo tests for a barrage of potential ailments, from anemia to prostate cancer. They

8 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

AmerisourceBergen first quarter revenues increase 3% to record $19.9 billion

AmerisourceBergen Corporation today reported that in its fiscal year 2011 first quarter, ended December 31, 2010, diluted earnings per share were $0.57, a 10 percent increase. Revenue in the quarter was a record $19.9 billion, up 3 percent.

4 Feb 2011

New way to stabilize proteins

A team of scientists at The Scripps Research Institute has discovered a new way to stabilize proteins — the workhorse biological macromolecules found in all organisms. Proteins serve as the functional basis of many types of biologic drugs used to treat everything from arthritis, anemia, and diabetes to cancer.

4 Feb 2011

Lead exposure can lead to high blood pressure in pregnant women: Study

Even minute amounts of lead may take a toll on pregnant women, according to a study published by Lynn Goldman, M.D., M.S., M.P.H., Dean of George Washington University's School of Public Health and Health Services in D.C., and colleagues, in the journal Environmental Health Perspectives.

3 Feb 2011

Anemia News and Research

Further Reading

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

2 bills to expand mental health coverage introduced

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Metallic copper surfaces kill bacteria on contact

Spirulina Pacifica supplement may improve immune function, anemia in senior citizens

Viewpoints: Expediting SCOTUS health law review; birth control funding; budget cutting and the stock market

State court jury rules in favor of Merck in FOSAMAX trial

SynthRx to become wholly-owned subsidiary of ADVENTRX

Silent strokes can cause long-term cognitive, learning deficits in children with sickle cell disease

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Mobily introduces first mobile medical imaging service

Gates Foundation awards USF $5.45M for malaria research

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Executive wellness a legit corporate expense

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

AmerisourceBergen first quarter revenues increase 3% to record $19.9 billion

New way to stabilize proteins

Lead exposure can lead to high blood pressure in pregnant women: Study

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News